CAR T-Cell Therapy Appears Promising in Relapsed/Refractory DLBCL
David Miklos, MD, discusses exciting data for the use of chimeric antigen receptor T-cell therapy as treatment of patients with diffuse large B-cell lymphoma.
Highlighting CAR T Cell Options for Relapsed/Refractory DLBCL
David Miklos, MD, discusses his advice for community oncologists treating patients with diffuse large B-cell lymphoma.